cesure

[ SEARCH ]

find a paper

Press Enter to search 200M+ papers via Semantic Scholar. Want something deeper? Run a Deep Discovery.

2,316,577 RESULTS

2020Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trialP. Gautret, J. Lagier, P. Parola et al. · International Journal of Antimicrobial AgentsHydxychloroquine treatment is significantly associated with viral load reduction/disappearance in COVID-19 patients and its effect is reinforced by azithromycin, which is significantly more efficient for virus elimination.2023Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial.J. Sims, Jennifer A. Zimmer, C. Evans et al. · Journal of the American Medical Association (JAMA)This randomized, double-blind, placebo-controlled, 18-month phase 3 trial enrolled 1736 participants with early symptomatic Alzheimer disease (mild cognitive impairment/mild dementia) with amyloid and low/medium or high tau pathology based on positron emission tomography imaging from June 2020 to November 2021 to assess efficacy and adverse events of donanemab.1972The randomized clinical trial.E. Glaser · New England Journal of Medicine2017Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical TrialR. Stupp, S. Taillibert, A. Kanner et al. · Journal of the American Medical Association (JAMA)In the final analysis of this randomized clinical trial of patients with glioblastoma who had received standard radiochemotherapy, the addition of TTFields to maintenance temozolomide chemotherapy vs maintenance Temozolmide alone, resulted in statistically significant improvement in progression-free survival and overall survival.2020Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial.Ling Li, Wei Zhang, Yu Hu et al. · Journal of the American Medical Association (JAMA)Among patients with severe or life-threatening COVID-19, convalescent plasma therapy added to standard treatment, compared with standard treatment alone, did not result in a statistically significant improvement in time to clinical improvement within 28 days.2022Lenvatinib Combined With Transarterial Chemoembolization as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Phase III, Randomized Clinical Trial (LAUNCH)Zhenwei Peng, W. Fan, Bowen Zhu et al. · Journal of Clinical OncologyThe addition of TACE to LEN improves clinical outcomes and is a potential first-line treatment for patients with advanced HCC.2011Sentinel Lymph Node Dissection With and Without Axillary Dissection in Women With Invasive Breast Cancer and Sentinel Node Metastasis: A Randomized Clinical TrialA. Giuliano, K. Hunt, K. Ballman et al. · Journal of the American Medical Association (JAMA)Among patients with limited SLN metastatic breast cancer treated with breast conservation and systemic therapy, the use of SLND compared with ALND did not result in inferior survival.1999A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group.Paul C. Hébert, G. Wells, M. Blajchman et al. · New England Journal of MedicineA restrictive strategy of red-cell transfusion is at least as effective as and possibly superior to a liberal transfusion strategy in critically ill patients, with the possible exception of patients with acute myocardial infarction and unstable angina.2016Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged ≥75 Years: A Randomized Clinical Trial.J. Williamson, M. Supiano, W. Applegate et al. · Journal of the American Medical Association (JAMA)Among ambulatory adults aged 75 years or older, treating to an SBP target of less than 120 mm Hg compared with an SBp target of more than 140mm Hg resulted in significantly lower rates of fatal and nonfatal major cardiovascular events and death from any cause.2023Addition of Metastasis-Directed Therapy to Intermittent Hormone Therapy for Oligometastatic Prostate Cancer: The EXTEND Phase 2 Randomized Clinical Trial.Chad Tang, A. Sherry, C. Haymaker et al. · JAMA OncologyPFS and eugonadal progression-free survival were significantly improved with combination treatment compared with hormone treatment only in men with oligometastatic prostate cancer, and combination of MDT with intermittent hormone therapy may allow for excellent disease control while facilitating prolonged eugenadal testosterone intervals.2021Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial.R. Gottlieb, A. Nirula, Peter Chen et al. · Journal of the American Medical Association (JAMA)The primary end point was change in SARS-CoV-2 log viral load at day 11 (±4 days), and nine prespecified secondary outcome measures were evaluated with comparisons between each treatment group and placebo, and included 3 other measures of viral load, 5 on symptoms, and 1 measure of clinical outcome.2021Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial.N. Al Kaabi, Yuntao Zhang, S. Xia et al. · Journal of the American Medical Association (JAMA)In this prespecified interim analysis of a randomized clinical trial, treatment of adults with either of 2 inactivated SARS-CoV-2 vaccines significantly reduced the risk of symptomatic COVID-19, and serious adverse events were rare.2023Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial.C. Raison, G. Sanacora, J. Woolley et al. · Journal of the American Medical Association (JAMA)Psilocybin treatment was associated with a clinically significant sustained reduction in depressive symptoms and functional disability, without serious adverse events, and this findings add to increasing evidence that p silocybin-when administered with psychological support-may hold promise as a novel intervention for MDD.2019Effect of Catheter Ablation vs Antiarrhythmic Drug Therapy on Mortality, Stroke, Bleeding, and Cardiac Arrest Among Patients With Atrial Fibrillation: The CABANA Randomized Clinical TrialD. Packer, D. B. Mark, R. Robb et al. · Journal of the American Medical Association (JAMA)Among patients with AF, the strategy of catheter ablation, compared with medical therapy, did not significantly reduce the primary composite end point of death, disabling stroke, serious bleeding, or cardiac arrest, which should be considered in interpreting the results of the trial.2020Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trialZhaowei Chen, Jijia Hu, Zongwei Zhang et al. · medRxivAmong patients with COVID-19, the use of HCQ could significantly shorten TTCR and promote the absorption of pneumonia.2016Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-year Results from a Comparative Effectiveness Randomized Clinical TrialJ. Wells, A. Glassman, Allison R. Ayala et al. · Ophthalmology (Rochester, Minn.)All 3 anti-VEGF groups had visual acuity improvement at 2 years with a decreased number of injections in year 2, and among eyes with worse baseline VA, aflibercept, on average, had superior 2-year VA outcomes compared with bevacizumab, but superiority of aflibercept over ranibizumab, noted at 1 year, was no longer identified.2022Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial.T. Conroy, F. Castan, A. Lopez et al. · JAMA OncologyThe final 5-year results from the PRODIGE 24/Canadian Cancer Trials Group PA6 randomized clinical trial indicate that adjuvant treatment with modified FOLFIRINOX yields significantly longer survival than gemcitabine in patients with resected pancreatic ductal adenocarcinoma.2020Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial.O. Hermine, X. Mariette, P. Tharaux et al. · JAMA Internal MedicineIn this randomized clinical trial of patients with COVID-19 and pneumonia requiring oxygen support but not admitted to the intensive care unit, TCZ did not reduce WHO-CPS scores lower than 5 at day 4 but might have reduced the risk of NIV, MV, or death by day 14, and no difference on day 28 mortality was found.2020Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial.C. Salvarani, G. Dolci, M. Massari et al. · JAMA Internal MedicineThis randomized clinical trial of hospitalized adult patients with COVID-19 pneumonia and Pao2/Fio2 ratio between 200 and 300 mm Hg who received tocilizumab found no benefit on disease progression was observed compared with standard care, and further blinded, placebo-controlled randomized clinical trials are needed.2020Favipiravir versus Arbidol for COVID-19: A Randomized Clinical TrialChang Chen, Yi Zhang, Jianying Huang et al. · medRxivAmong patients with COVID-19, Favipiravir, compared to Arbidol, did not significantly improve the clinically recovery rate at Day 7 and FavipIRavir significantly improved the latency to relief for pyrexia and cough.1999A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD.P. Jensen, L. Arnold, Je Richters et al. · Archives of General PsychiatryThe authors' carefully crafted medication management was superior to behavioral treatment and to routine community care that included medication for ADHD symptoms, and may have provided modest advantages for non-ADHD symptom and positive functioning outcomes.2020Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial.C. Spinner, R. Gottlieb, G. Criner et al. · Journal of the American Medical Association (JAMA)Among patients with moderate COVID-19, those randomized to a 10-day course of remdesivir did not have a statistically significant difference in clinical status compared with standard care at 11 days after initiation of treatment, but the difference was of uncertain clinical importance.2019Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma: A Phase 2 Randomized Clinical Trial.E. O’Reilly, D. Oh, N. Dhani et al. · JAMA OncologyTreatment was well tolerated, and the efficacy of durvalumab plus tremelimumab therapy and durvalUMab monotherapy reflected a population of patients with mPDAC who had poor prognoses and rapidly progressing disease.2017Effect of Continuous Glucose Monitoring on Glycemic Control in Adults With Type 1 Diabetes Using Insulin Injections: The DIAMOND Randomized Clinical TrialR. Beck, Tonya D. Riddlesworth, K. Ruedy et al. · Journal of the American Medical Association (JAMA)Among adults with type 1 diabetes who used multiple daily insulin injections, the use of CGM compared with usual care resulted in a greater decrease in HbA1c level during 24 weeks.2019A 3-year Randomized Clinical Trial of MiSight Lenses for Myopia ControlP. Chamberlain, S. C. Peixoto-de-Matos, N. Logan et al. · Optometry and Vision ScienceResults of this clinical trial demonstrate the effectiveness of the MiSight daily disposable soft contact lens in slowing change in spherical equivalent refraction and axial length.